Recently Featured

Ionis’ Rare Neurology Drug Zanvastro Approved; Pfizer Inks ADC Deal

September 23, 2026
Ionis Pharmaceuticals has received FDA approval for Zanvastro, marking a significant milestone as it becomes the first medicine approved for the treatment of Alexander disease, a rare and debilitating neurological disorder. This approval not only underscores the growing recognition of niche therapeutic areas within the pharmaceutical landscape but also highlights Ionis’ commitment to addressing unmet…

AZ Leverages AI-Generated Llama to Market Breztri Inhaler in Innovative Campaign

September 23, 2026
AstraZeneca has launched a new advertising campaign for its LAMA combination inhaler, Breztri, featuring an AI-generated llama as its central character. This creative approach aims to engage healthcare professionals by presenting the llama and its barnyard companions working late in an office setting, reinforcing the message to “put a LAMA to work” for patients. The…

PRAC Initiates Review of Injectable Iron Medicines Due to Safety Concerns

September 23, 2026
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency has commenced a review of injectable iron medicines, focusing on the potential risks associated with low blood phosphate levels and related bone problems. This review highlights the regulatory body’s proactive approach to ensuring patient safety amidst growing concerns regarding the safety profiles of these…

The CDMO Capacity Crunch Persists

September 23, 2026
Contract development and manufacturing organizations (CDMOs) are grappling with persistent capacity constraints as demand for biopharmaceutical manufacturing surges. A recent survey by BioPlan Associates reveals that nearly half of biopharma companies report significant challenges in securing CDMO capacity, particularly for mammalian production, where 49% of respondents indicated difficulties. This is an increase from previous years,…

Ongoing Cases